Mizuho Reiterates Outperform Rating on Neumora Therapeutics (NMRA)

Mizuho analyst Graig Suvannavejh reiterated an Outperform rating and $20.00 price target on Neumora Therapeutics (NASDAQ: NMRA).

The analyst commented: "This week, we had an opportunity to meet with NMRA CEO Henry Gosebruch and Head of IR Helen Rubenstein. Key topics discussed included (1) the current pivotal Phase 3 KOASTAL 1-3 studies for lead asset navacaprant (a novel kappa opioid receptor antagonist/KORA) for major depressive disorder/MDD, (2) expectations around a positive outcome from those studies, (3) NMRA's Alzheimer's disease/AD agitation efforts with NMRA-511 (a novel vasopressin 1a receptor/V1aR antagonist), and (4) the current status of NMRA's muscarinics portfolio for schizophrenia. Net net, we came away positively from the meeting, and with our overall enthusiasm and confidence in navacaprant's prospects for Phase 3 success maintained, we reiterate our Outperform rating on NMRA."

For an analyst ratings summary and ratings history on Neumora Therapeutics click here. For more ratings news on Neumora Therapeutics click here.

Shares of Neumora Therapeutics closed at $10.79 yesterday.

You May Also Be Interested In

• Phillips 66, Marathon Merger Talks Collapsed - Semafor
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating
• Active options: TSLA NVDA SPCX MU AAPL AMD INTC AMZN